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Abstract
Background: The reporting of adverse drug reactions (ADR) by patients represents an interesting challenge in the
field of pharmacovigilance, but the reporting system is not adequately implemented in France. In 2015, only 20 MS
patients in France reported ADR due to first-line disease-modifying drugs (DMD), while more than 3000 patients
were initiated on DMD.
The aim of this study is to validate a proof-of-concept as to whether the use of a mobile application (App) increases
ADR reporting among patients with relapsing-remitting multiple sclerosis (RR-MS) receiving DMD.
Methods/design: We designed a multi-centric, open cluster-randomized controlled trial, called the Vigip-SEP
study (NCT03029897), using the App My eReport France® to report ADR to the appropriate authorities in E2B
language, in accordance with European regulations. RR-MS patients who were initiated on, or switched, first-line DMD
will be included. In the experimental arm, a neurologist will introduce the patient to the App to report ADR to the
appropriate French authorities. In the control arm, the patient will be informed of the existence of the App but will not
be introduced to its use and will then report ADR according to the usual reporting procedures. Primary assessment
criteria are defined as the average number of ADR per patient and per center. We assume that the App will increase
patient reporting by 10-fold. Therefore, we will require 24 centers (12 per arm: 6 MS academic expert centers, 3 general
hospitals, 3 private practice neurologists), allowing for an expected enrollment of 180 patients (alpha risk 5%, power 90%
and standard deviation 4%).
Discussion: Increasing patient reporting of ADR in a real-life setting is extremely important for therapeutic management
of RR-MS, particularly for monitoring newly approved DMD to gain better knowledge of their safety profiles. To increase
patient involvement, teaching patients to use tools, such as mobile applications, should be encouraged, and
these tools should be tested rigorously.
Trial registration: ClinicalTrials.gov, ID: NCT03029897. Registered on 20 January 2017.
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Background
Adverse drug reactions (ADR) constitute some of the
major causes of morbidity and mortality worldwide. It is
estimated that ADR account for more than 5% of
hospital admissions, 28% of emergency department visits
and 5% of deaths during hospitalization [1]. Thus, ADR
caused approximately 200,000 deaths per year in Europe
and generated costs of 79 million euros in 2015 alone [2].
Spontaneous reporting of ADR is the backbone of
the pharmacovigilance system and has been proven to
play a role in identifying signs related to drug safety.
Descriptions of the safety profiles of drugs during clinical
development are not exhaustive and do not reflect poten-
tially late or rare occurrences of ADR [1]. Spontaneous
reporting by health care professionals in subsequent post-
marketing settings is the greatest source of drug safety
data [3]. However, under-reporting of ADR is a key limita-
tion of the efficiency of pharmacovigilance systems, and
spontaneous reporting by patients is now recognized as a
new source of information for these systems.
A recent review of the academic literature confirmed
that patient reporting adds new information about ADR:
such reporting provides a more detailed description of
ADR that differs in terms of the nature of the reaction
and the suspected drugs involved [4]. In the Netherlands
from 2010 to 2015, patients made important contribu-
tions by reporting 26% of all ADR reports [3, 5]. The
Danish Medicines Agency published a report on ADR
reported by consumers compared with reports from
health care professionals covering the period from 2003
to 2011 and showed that consumer reports contribute
significantly to the total number of ADR reports, both
quantitatively and qualitatively [6]. Patient self-reporting
was also investigated in the United Kingdom (UK) in the
UK’s Yellow Card Scheme from 2005 to 2007, and the
results also suggested that patient reporting provides a
positive complementary contribution to health profes-
sional reporting [7, 8]. In France, during the pandemic in-
fluenza vaccination campaign in 2009–2010, a
pharmacovigilance plan was introduced following the rec-
ommendations of the European Medicines Agency
(EMA). For the first time in France, patients were able to
report ADR concerning the pandemic vaccine directly to
pharmacovigilance centers. This study revealed no major
qualitative differences between patients’ and health profes-
sionals’ reports [9]. Despite growing interest and accept-
ance of ADR reporting by patients [10, 11], few studies
have validated the relevance of data from patient notifica-
tions [12–14].
Health authorities in 44 countries currently emphasize
spontaneous ADR notifications by patients and the need
for a more accessible reporting system [15]. According to
new European legislation (Directive 2010/84/EU), member
states are required to establish an ADR reporting system
for patients. Since 2011, patients in France have been able
to self-report their ADR without involving a health profes-
sional. The French pharmacovigilance system is based on
31 regional drug monitoring centers and a dedicated unit
of the French Agency “Agence nationale de la sécurité du
médicament et des produits de santé (ANSM).” Patients
can report ADR either directly to ANSM via a form that is
available at http://ansm.sante.fr/ or to a regional center
electronically or by telephone. However, patient reporting
in France remains underdeveloped, and its availability is
not widely known by the general population [16]. For ex-
ample, in 2014, ADR reported by patients represented
4.5% of all reports, compared with 10% in Europe,
according to data from the French National Database
of Pharmacovigilance [16]. Most patients remain un-
aware of reporting systems or are confused about
reporting [17].
Therefore, “e-health” applications could be a conveni-
ent method to more closely connect with patients [18].
It has been demonstrated that the use of mobile applica-
tions to report adverse events, such as those related to a
medical device, can save time and increase the number
of notifications. On average, there were 15 times more
reports submitted per month via the App MedWatch®
with patient community support than submitted via
traditional pharmacovigilance portals [19].
In 2016, it was estimated that 50% of the population
and 99% of young physicians in France own a smart-
phone. The most widely used medical Apps by young
physicians are Apps related to drugs (drug database,
drug interaction database) [20]. A smartphone/tablet
application seems to be a necessity for modern pharma-
covigilance approaches (i.e., MedWatcher® in USA or
YellowCArd® in UK).
In France, several applications dedicated to ADR
reporting are available on the market (i.e., VigiBip®, My
e-Report®, Medisafe®), but these applications are not yet
widely used by patients. For example, in the Toulouse
University Pharmacovigilance Center, patient reports
submitted by the App VigiBip® (6.7% of total reports
received by the center) were significantly more fre-
quent than those submitted via classical methods
(3.4%) (p = 0.01) [21].
To further promote patient involvement, teaching
tools, such as mobile applications, should be encour-
aged, and these tools should be tested rigorously.
Population
During the past years, different new disease-modifying
drugs (DMD) have become available on the market for
multiple sclerosis (MS) care, although most of these
drugs induce significant general and biological side
effects. While these new treatments offer important
medical benefits, they also require close monitoring,
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which has led to the implementation of risk management
plans (RMP). Clinical trial populations are homogenous
and rigorously followed, whereas under-reporting by
patients is undeniable in normal clinical practice.
Hence, increasing the rate of spontaneous reports of
ADR by MS patients would represent a significant con-
tribution to the pharmacovigilance system. MS occurs in
young adults, which is a population that is accustomed
to the use of smartphones and Apps. Therefore, utilizing
an App to report ADR could stimulate spontaneous
reporting by patients.
According to data extracted on 15 December 2016 from
the French MS Observatory “Observatoire Français de la
Sclérose en Plaques (OFSEP)” based on an analysis of the
French patient cohort EDMUS (http://www.ofsep.org/fr/
la-cohorte-ofsep/descriptif-de-la-cohorte), each year, 5000
new patients are diagnosed with MS in France. The distri-
bution of the various forms of MS is as follows: 79%
relapsing-remitting multiple sclerosis (RR-MS), 11%
progressive MS and 10% a clinically isolated syndrome.
This trial will focus on patients with RR-MS, as these
patients are involved in the management and monitoring
of their pathology, with a population of 3950 newly diag-
nosed individuals per year in France. Furthermore, we
know that 25% of RR-MS patients do not receive DMD
(extracted from OFSEP). Thus, approximately 3000 first-
line DMD evaluated in RR-MS patients are introduced per
year in France. First-line DMD include interferon β,
peginterferon β, glatiramer acetate, teriflunomide, and di-
methyl fumarate.
Intervention
All patients included in Vigip-SEP will be informed that
they can report their ADR using a pharmacovigilance
system. They will also be informed of the existence of
the App My eReport France® developed to report ADR
in accordance with European and French regulations. In
experimental centers, patients will be introduced to its
use by neurologists. In control centers, they will not be
introduced to its use but will be encouraged to report
ADR through usual reporting methods.
The My eReport France® application was chosen for
the Vigip-SEP study, developed by the eVeDrug® society,
to report ADR to the appropriate French authorities in
E2B language, in accordance with European regulations.
The application is certified by the label “My health qual-
ity.” Data hosting is provided by a certified health data
host. Updates are performed automatically according to
the evolution of E2B regulations.
Comparison
The mean number of ADR per patient at the center will
be compared between interventional and control centers.
Outcome
The principal aim of the Vigip-SEP study is to validate a
proof-of-concept: Does the use of a mobile application
(App) increase ADR reporting in RR-MS patients receiv-
ing first-line DMD?
Methods/design
Aim, design and setting
The overall aim of our Vigip-SEP trial is to study reporting
of ADR by RR-MS patients using a mobile application.
The first aim is to evaluate the increase in ADR report-
ing by mobile application use. The second aim is to evalu-
ate the quality of patient reporting. We will also evaluate
the effect of patient involvement in pharmacovigilance on
physician reporting (boost effect). Additionally, the user-
friendliness of the application will be assessed according
to the patients’ satisfaction, the patients’ judgment of prac-
ticability, and the patients’ suggestions for improvements.
The designed study is a multi-centric, open cluster-
randomized controlled trial.
The Vigip-SEP study is set in France. The trial sponsor
is CHU de Caen, an academic hospital, responsible for
protocol decisions and quality control. Coordination is
provided by an investigative team of MS academic
experts at the center of CHU de Caen.
This study was approved by the Ethics Committee of
Nord-Ouest III with approval number 2016–42. The
privacy of the participants and their personal medical
records will be guaranteed by treating the data according
to the French law n. 78–17 of 6 January 1978 and the
“European Union Data Protection Directive (95/46/EC
24 October 1995).”
The approved version of Vigip-SEP is V3 29.11.2016;
the recruitment began in June 2017, and the end date is
anticipated in May 2018.
The sponsor CHU de Caen is responsible for reporting
any protocol modifications to the centers, ethic commit-
tees and ANSM.
Subjects
To be eligible for participation, subjects must meet the
following defined inclusion criteria:
Men or women aged ≥ 18 years with RR-MS
Patients undergoing the initiation of a first-line DMD
(interferon β, peginterferon β, glatiramer acetate,
teriflunomide, and dimethyl fumarate). Patients without
ulterior first-line DMD or patients benefiting from a
change in treatment between first-line DMD (switch)
Patients who have access to a smartphone, tablet or
other computer device that can host the selected
mobile application
Patients benefiting from the French Social Security
system
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Satisfactory level of comprehension and expression in
French
Patients who provided written informed consent
Subjects meeting any one of the following exclusion
criteria may not be eligible to participate in the study:
Patients with secondary or primary progressive MS
Patients with MS who are not being treated with a
first-line DMD
Description of all processes (see Fig. 1)
Randomization
The biostatistician of the sponsor CHU de Caen will
perform the randomization. Randomization will be
performed using the ALEA function of Microsoft Excel
2013.
Centers will be stratified based on structure type then
randomly allocated (1:1) to the experimental arm (these
centers will introduce all patients to use of the App) or
to the control arm (these centers will not introduce
patients to use of the App). Centers will be informed of
the randomization the day of the trial initiation visit.
Clustering avoids a “contamination” bias (in the
epidemiological sense) of different patients followed by
the same prescriber.
Neurologists will successively include all patients
meeting the criteria until they have reached the number
of subjects to be included. In 1 year, MS academic expert
centers are expected to include 10 patients, and general
hospitals and private practice neurologists are expected
to include 5 patients. Neurologists will inform patients
about the Vigip-SEP study and obtain the patients’ writ-
ten informed consent.
CHU de Caen conforms to National Informatic and
Liberty French Law and, therefore, patient confidential-
ity will be protected.
Intervention arm
In the experimental arm, the patient is introduced to use
of the App by a neurologist.
A video tutorial created by the investigator’s staff of
the Vigip-SEP study is presented to the patient.
The patient is able to report his ADR via the mobile
application. The report is electronically sent directly to
the regional pharmacovigilance center, which assesses
Fig. 1 Enrollment, interventions and assessments in the Vigip-SEP study
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the case, and after treatment, records it in the national
competent authority database in the usual manner.
Patients can also describe their ADR to their physician
during consultation. A physician who is informed of an
ADR by his patient is able to report it as usual (via the
mobile application or via the conventional methods of
reporting), and duplicate reports will be identified a
posteriori.
A follow-up questionnaire will be administered to pa-
tients by telephone call during the study at 1 month (± 15
days). The patient will be asked if they had ADR and, if so,
whether they reported the ADR and how. Education
regarding the application will be monitored, and the user-
friendliness of the application will also be evaluated by the
patients’ satisfaction, practicability and suggestions.
Control arm
In the control arm, no intervention is performed except
for follow-up questionnaires at 1 and 6 months. The
patient is informed of the existence of the App but is
not introduced to its use. The patient reports ADR
according to the usual reporting procedures.
In both arms, any concomitant care is allowed. Usual
care will be conducted in the post-trial period.
Outcome measurements
Primary outcomes
The primary outcome is the number of ADR patient
reports. ADR reports will be collected in both arms for 6
months after the inclusion of each patient from the
national database of French authority, ANSM (see “Data
collection procedure” below).
An example of the method of aggregation is as follows.
For center 1, m1 = n1 reports/N1 patients, where n1 is
the number of ADR in the center, and N1 is the number
of patients included in the center.
The method of aggregation in each group follows the
formula Ʃmx/N, where N is the number of centers in the
group.
Secondary outcomes
Each reaction is assessed by a regional pharmacovigi-
lance center with a MedDRA coding. The profile of the
ADR per drug classified by System Organ Class will be
compared with the safety post-marketing profile in the
Summary of Product Characteristics.
The number of physician reports will be compared
between the two arms to measure the “boost” effect of
patient reporting via the mobile application.
The user-friendliness of the application will be evalu-
ated by analyzing the responses to the questionnaire
completed at 1 month (± 15 days).
The feedback from the regional pharmacovigilance
center will be evaluated by analyzing the responses to
the questionnaire completed at 6 months (± 15 days).
Data collection procedure
The data manager of CHU de Caen is responsible for
form development, sponsor database development and
data management.
Regardless of how ADR are reported, they are sent to
a regional pharmacovigilance center for assessment,
which includes MedDRA coding and causality analysis.
Then, the regional pharmacovigilance center records the
ADR in the national database.
At the end of the study, the 31 regional centers of
pharmacovigilance will anonymously extract ADR
reports pertaining to the first-line DMD in the trial
period from the national database. The investigator’s
team will identify reports of the Vigip-SEP population
(of the two groups), and the Vigip-SEP investigators will
compare the received date and the region, age and sex
of the patient. ADR reported by patients within the 6
months of inclusion and by neurologists within the same
period will be recorded in the sponsor database. Duplicates
(the same ADR reports made by patients and physicians)
will then be identified.
Data collected regarding the investigating centers will
include the following:
Type of structure: MS academic expert center, general
hospital, private practice neurologist
Date and result of randomization
Date of implementation
Regional pharmacovigilance center attached to the
investigating center
Data collected regarding patients will include the
following:
Socio-demographic information: patient initials, date of
birth and gender
Confirmation of diagnosis of RR-MS and date of
diagnosis
EDSS (Expanded Disability Status Scale) score at the
time of inclusion
Date of inclusion
Name and date of initiation of first-line DMD
prescribed
Name of previous first-line DMD if the patient is not
naïve of any MS treatment
If a switch occurred in MS treatments during the
course of the study, date of the current first-line DMD
discontinuation and name and date of initiation of the
new first-line DMD
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Adverse events: method of reporting, description,
date, first-line DMD concerned, MedDra code, and
expectedness (a previously known adverse reaction
and its frequency, listed in the summary of the product
characteristics of the drug)
Responses to the questionnaire at 1 month (± 15 days),
ADR, method of reporting, and friendliness of App
(only in the experimental arm)
Response to the questionnaire at 6 months (± 15 days)
regarding feedback from the regional
pharmacovigilance center
Data analysis
The statistical analysis will be carried out by the Vigip-
SEP scientific team.
Hypothesis
In the academic literature, no study has measured the
impact of an App on increasing reports of ADR by
patients. MedWatcher® is a user-friendly reporting App
used to prepare and submit an adverse event report to
the Food and Drug Administration for a hysteroscopic
sterilization device. In 2012, a patient social media
community adopted MedWatcher® to declare adverse
reactions related to the device. On average, there were
15 times more reports via the App than via the trad-
itional pharmacovigilance portal [19]. We assume that
patient reporting will increase by 10-fold with the use of
the mobile application My e-Report® over the traditional
reporting method.
To follow the cluster-randomized design, the statistical
unit will be the center. Therefore, the average number of
ADR patient reports per patient will be pooled by center,
and the comparison will be performed at the cluster
(center) level. Estimation of number of centers required:
this is a comparison of two means with an average for
the arm standard of 20/3000 = 0.0067 or 6.7 per 1000
patients; and for the interventional arm of 200/3000 =
0.067 or 67 per 1000 patients. The power is 90% accord-
ing to a bilateral test with 5% error risk and an estimated
standard deviation of 0.04. Therefore, 10 centers in each
arm are needed to test our hypothesis.
We will target to include 12 centers per arm to
counter the trend in over-reporting due to informing
physicians of the study (inflation factor). A total of 24
MS outpatient-clinic departments will recruit 180
patients (90 per arm) with the following distribution
according to structure type: 10 patients per MS aca-
demic expert center, 5 patients per general hospital
and 5 patients per private practice neurologist.
Statistical criteria for stopping the study: no inter-
mediate analysis is planned, and the study will be
stopped when all centers have obtained the required
number of patients.
Method for accounting for missing, unused or invalid
data: the patient is first informed of the study, and then,
the patient’s statements are collected for 6 months. Each
patient will be contacted by telephone 1 month (± 15
days) after inclusion. The 1-month follow-up question-
naire will be used to determine whether the patient
should be removed from the study and replaced accord-
ing to the following considerations:
If the patient has reported at least one ADR, the
patient data are preserved
If the patient did not report an ADR:
 Because they had no ADR, the patient data are
preserved
 Because they did not like the method of reporting,
the patient data are preserved
 For technical reasons (loss or breakage of the
telephone/tablet), the patient is replaced by another
patient, and these data are not analyzed
The sponsor CHU de Caen applies random audits of
their trials of low-risk studies. The experimental inter-
vention, defined as “Introduction to the App,” is not a
risk for patients included in Vigip-SEP, and therefore, a
safety monitoring board was not necessary.
There is no plan to provide access to the final data to
anyone beyond the investigators.
Statistical analysis plan
A biostatistician will compare the mean number of ADR
per patient at the center level by using Student’s t test or
Wilcoxon’s rank test, as appropriate, with the number of
enrolled patients in each center as a weighting factor. In
addition, the biostatistician will generate hierarchical
models (level 1: centers; level 2: physicians nested within
centers; level 3: individuals nested within physicians)
with an analysis at the level of the patient taking into
account the intra-cluster correlations at different levels
using a generalized linear model. This analysis will have
the advantage of controlling for potential confounders at
the individual and physician level. The results will be
reported using the Consolidated Standards of Reporting
Trials (CONSORT) criteria (see Additional file 1).
We further plan to communicate these results to
pharmacologist and neurologist review and to congress.
Discussion
Application use by patients could be an integral part of
the pharmacovigilance system that is in place in France.
This study aims to improve the efficiency of the pharma-
covigilance system by increasing the number of reports
and, therefore, allowing earlier detection of events to
prevent and minimize risks.
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The robust methodology, with a clustered randomized
national study, will determine the usefulness of national
support for reporting by mobile application.
The results of this study should be available in the
summer of 2018, and we hope that these results will be
consistent with our assumption that (1) the efficiency of
the post-marketing authorization system will be improved
by an increase in reporting of ADR via the mobile
application and (2) the therapeutic safety of MS
patients will be improved by a better knowledge of the
safety profile of DMD.
Developing a culture of reporting ADR by RR-MS
patients is a relevant goal. In 2015, in France, 20 ADR
were reported by MS patients compared with 271 ADR
reported by physicians concerning first-line DMD ac-
cording to data from the French National Database of
Pharmacovigilance. In the future, we hope that this new
method of reporting will improve pharmacovigilance by
RR-MS patients and can be extended to include all new
DMD. The overall goal is to be able to improve the early
detection of unexpected adverse reactions not revealed
by clinical consultations. If our hypothesis is con-
firmed, other neurological diseases could be explored
using this method.
Strengths and limitations
This study has several strengths. First, the design, a
randomized control trial, will allow a causal interpret-
ation in terms of outcomes. In addition, including
several types of centers (academic expert centers, general
hospitals and private practice neurologists) will increase
the external validity of the results. Furthermore, the
study is focused on the use of an innovative tool, a mo-
bile application, by a population in real-life conditions.
We are also aware of several potential limitations. This
is an open trial and, therefore, over-reporting due to
informing the patients and physicians is expected and
cannot be neutralized. Moreover, patients failing to
report ADR by the App may have had a technical prob-
lem or may have forgotten to report the ADR. Indeed,
the user-friendliness of the mobile application has not
been tested. To counter this limitation, 1 month after
inclusion, we will ensure by a telephone call that patients
report all ADR and are able to use the mobile application
effectively. Feedback from regional pharmacovigilance
centers will also be investigated by a telephone call at 6
months after inclusion to explore patient satisfaction [16].
Currently, patients describe ADR via the App via free
verbatim that is later coded by pharmacologists of phar-
macovigilance centers using the MedDra dictionary.
Encouraging this reporting requires the accompaniment
of regional pharmacovigilance centers. In addition,
informing patients, as proposed in the study, requires
time by neurologists. Financial resources should be put
in place for this support, which could be included, for
example, in a patient education program.
Pharmacovigilance is a major public health issue. First-
line DMD, whose risk profiles are not fully known, that
have been newly released to the market must be carefully
monitored. Patient involvement in the pharmacovigilance
system is already accepted to be a valuable asset but must
be further developed. RR-MS patients, who are already
well-adapted to managing their disease, could be key
players in effective pharmacovigilance. In a second phase,
we plan to develop applications specifically dedicated to
new DMD.
Trial status
Recruitment has not been completed at the time of this
submission.
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Additional file 1: SPIRIT 2013 Checklist: recommended items to address
in a clinical trial protocol and related documents*. (DOCX 49 kb)
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